44,879 new cases bring India’s COVID-19 tally to 87,28,795


Coronavirus cases in India: The case fatality rate of COVID-19 cases has fallen further to 1.47%. (Representative)

New Delhi:

India’s COVID-19 tally rose to 87.28 lakh on Friday with a one-day increase of 44,879 cases, while recoveries soared to 81.15580, pushing the national recovery rate to 92.97%, according to the Union Ministry of Health.

The death toll reached 128,668 after an additional 547 deaths were reported in the country in 24 hours and the total number of coronavirus cases climbed to 87,28,795, according to data updated at 8 a.m.

The case fatality rate of COVID-19 has fallen further to 1.47%.

There are 4,844,547 active cases in the country, representing 5.55% of the total number of cases, according to the data.

According to the ICMR, a cumulative total of 12,31,01,739 samples have been tested to date with 11,39,230 samples tested on Thursday.

Here are the live updates on the coronavirus cases:

India to receive 100 million Oxford vaccines by December: Adar Poonawalla

The world‘s largest vaccine maker is ramping up production of AstraZeneca’s Covid-19 vaccine, with a goal of having 100 million doses ready by December for an inoculation campaign that could begin across India on same month.

If data from the final trial shows AstraZeneca’s candidate offers effective protection against the virus, the Serum Institute of India – which has partnered to produce at least one billion doses – could get emergency clearance from New Delhi by December, said Adar Poonawalla, chief executive officer of the Pune-based family business.

That initial amount will go to India, Poonawalla said in an interview Thursday. Full approval early next year will allow 50-50 distribution with the South Asian nation and Covax, the World Health Organization-backed body that buys injections for poor countries.

Serum, which has partnered with five developers, has so far produced 40 million doses of AstraZeneca vaccine in the past two months and aims to start manufacturing the Novavax candidate soon.

“We were a little worried that this was a big risk,” said Poonawalla, 39. But AstraZeneca and Novavax’s plans “are pretty good”.


Please enter your comment!
Please enter your name here